Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
US Army
Chubb
McKesson
Teva
Citi
Mallinckrodt
Cantor Fitzgerald
Queensland Health

Generated: June 19, 2018

DrugPatentWatch Database Preview

ALLERGAN Company Profile

« Back to Dashboard

Summary for ALLERGAN

Drugs and US Patents for ALLERGAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc ANDRODERM testosterone FILM, EXTENDED RELEASE;TRANSDERMAL 020489-003 Oct 20, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes 8,986,715 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-002 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770-001 Aug 19, 2005 RX Yes Yes 6,627,210*PED ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ALLERGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-002 Sep 29, 2000 5,089,509 ➤ Sign Up
Allergan Sales Llc NAMENDA memantine hydrochloride TABLET;ORAL 021487-001 Oct 16, 2003 5,614,560 ➤ Sign Up
Allergan OPTICROM cromolyn sodium SOLUTION/DROPS;OPHTHALMIC 018155-001 Oct 3, 1984 3,686,412 ➤ Sign Up
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 5,863,560 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-23
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 2008-12-22
➤ Subscribe Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg ➤ Subscribe 2011-12-19
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 2006-11-03
➤ Subscribe Suppository 1000 mg ➤ Subscribe 2013-05-24
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 2008-10-14
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 2014-07-30
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 2015-01-21
➤ Subscribe Ophthalmic Solution 0.40% ➤ Subscribe 2005-01-28
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 2014-08-12
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 2008-08-19
➤ Subscribe Gel 7.5% ➤ Subscribe 2017-02-13
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 2010-05-03
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 2017-07-25
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 2011-04-05
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-24
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 2006-12-20
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09
➤ Subscribe Ophthalmic Solution 0.2%/0.5% ➤ Subscribe 2008-11-21
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 2013-01-14
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 2014-10-29
➤ Subscribe Ophthalmic Solution 0.30% ➤ Subscribe 2007-07-19
➤ Subscribe Gel 10% ➤ Subscribe 2014-06-19
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 2016-08-30
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 2009-03-02
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2017-06-09
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2010-12-07
Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Non-Orange Book US Patents for ALLERGAN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,635,675 Method of treating chronic fatigue syndrome ➤ Sign Up
8,877,793 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists ➤ Sign Up
7,387,788 Pharmaceutical compositions of nicotine and methods of use thereof ➤ Sign Up
2,014,073,571 ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for ALLERGAN Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
02C/039 Belgium ➤ Sign Up PRODUCT NAME: ESCITALOPRAM. OXALAT. (INN) ESCITALOPRAM; NATL. REGISTRATION NO/DATE: 7004 IE10 F 3 20020729; FIRST REGISTRATION: SE 17084 20011207
C0018 France ➤ Sign Up PRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
00110 Netherlands ➤ Sign Up PRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022
90007-7 Sweden ➤ Sign Up PRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE ENANTIOMER, DIASTEREOMER, RACEMATE OR SALT THEREOF; REG. NO/DATE: EU/1/16/1126 20160921
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Colorcon
Farmers Insurance
Medtronic
Covington
US Department of Justice
Fuji
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.